Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,118 across all filing types
Latest filing 2022-11-29 AGM Information
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Chairman's Address to Shareholders 5 pages 269.7KB
AGM Information Classification · 95% confidence The document is a detailed Chair's address delivered at Mayne Pharma Group Limited's 2022 Annual General Meeting (AGM). It includes procedural details about the meeting, introductions of board members and executives, a summary of the company's strategic initiatives, financial highlights for FY22, and future outlook. The text explicitly states it is the Chair's address at the AGM and references the meeting date and location. There is no indication that this is a full annual report or financial statement, nor is it a brief announcement or proxy solicitation. The content aligns with materials typically shared during an AGM, such as the Chair's speech and business updates. Therefore, the document fits the category of AGM Information (AGM-R). The document length (over 11,000 characters) supports that it is a substantive AGM presentation rather than a short announcement or notice.
2022-11-29 English
Results of Meeting 2 pages 294.8KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal communication to the ASX Limited regarding the results of resolutions passed at the Mayne Pharma Group Limited Annual General Meeting (AGM). It references Listing Rule 3.13.2 and section 251AA of the Corporations Act, which pertain to the disclosure of voting results. The text explicitly states it is providing details of the results of the resolutions and proxies received, and confirms that all resolutions were approved. The document length is short (803 characters) and it is focused solely on announcing the voting outcomes from the AGM, not the AGM materials or the full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-11-29 English
Mayne Pharma capital management update 2 pages 156.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 28 October 2022 from Mayne Pharma Group Limited. It announces capital management initiatives including a special dividend, a pro rata return of capital subject to shareholder approval, and a share consolidation. It references the upcoming Annual General Meeting (AGM) where shareholder approval will be sought. The document is relatively short (4199 characters) and primarily serves as an announcement of these capital actions and related shareholder meeting information. It does not contain detailed financial statements or comprehensive financial analysis. It also refers readers to the AGM Notice of Meeting for further details. Therefore, this document is best classified as a Capital/Financing Update (CAP) because it provides updates on company fundraising, financing activities, or capital structure changes, specifically dividend and capital return announcements and share consolidation plans.
2022-10-27 English
2022 AGM Notice of meeting and shareholder pack 22 pages 1.6MB
AGM Information Classification · 100% confidence The document is a detailed notice and related materials for the 2022 Annual General Meeting (AGM) of Mayne Pharma Group Limited. It includes the Notice of Meeting, proxy form information, details on how to participate in the AGM, the agenda including election of directors, adoption of remuneration report, capital management resolutions, and instructions for voting. The document is not the actual annual report or financial statements but rather the official meeting notice and related shareholder communication for the AGM. It is not a report publication announcement since it contains substantive meeting details and proxy information. Therefore, the document fits the category of AGM Information (AGM-R).
2022-10-27 English
Consolidation/Split - MYX 5 pages 28.4KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Notification of Consolidation/Split' and details a security consolidation event for Mayne Pharma Group Limited. It includes specifics such as the consolidation ratio, record dates, trading dates, and adjustments to option exercise prices. The content focuses on changes to the company's capital structure through a security consolidation, which is a capital change event. There are no financial statements, earnings data, or management commentary present. The document is a formal announcement of a capital restructuring event rather than a report or financial statement. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (6162 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2022-10-27 English
Dividend/Distribution - MYX 8 pages 187.4KB
Notice of Dividend Amount Classification · 100% confidence The document is an Appendix 3A.1 form titled 'Notification of dividend / distribution' submitted to the ASX. It contains detailed information about a dividend announcement, including entity details, dividend type (special dividend), record date, ex date, payment date, and franked status. The content is regulatory in nature, specifically focused on dividend notification rather than a full financial report or earnings release. It is not a report publication announcement since it contains substantive dividend details, not just a notice of report availability. It is not an earnings release or annual/interim report. The document fits the definition of a Notice of Dividend Amount (DIV) as it announces dividend amounts, payment dates, and related details for shareholders.
2022-10-27 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.